Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
- Research interviews
-
1. The regulation of cell therapy
- Prof. Moutih Rafei
-
2. Artificial intelligence in guiding cancer treatment decisions
- Prof. Eytan Ruppin
-
3. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
4. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
5. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
-
6. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
7. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
8. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
9. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
10. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
12. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
13. MassBank development and future
- Dr. Emma L. Schymanski
-
14. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
15. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
17. PANDAS: a potential link between group A streptococcal infections and neurological disorders
- Prof. P. Patrick Cleary
-
18. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
19. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Clinical interviews
-
20. Monkeypox: etiopathogenesis, prevention, and treatments
- Dr. Dennis Hruby
-
21. Kidney xenotransplantation
- Dr. Douglas J. Anderson
-
22. CAR-T and TCR-T cellular immunotherapies in oncology
- Prof. Sebastian Kobold
-
23. MAPS: the business of medical affairs
- Dr. Danie du Plessis
-
24. Hypertrophic cardiomyopathy: therapies and treatments
- Prof. Srihari Naidu
-
25. Combating the HIV epidemic
- Prof. William Blattner
-
26. Epigenetic pharmaceuticals used in the clinic
- Dr. Thomas Paul
-
27. Precision cancer medicine: development and future
- Prof. Maurie Markman
-
28. Pediatric cancer testing
- Prof. Joshua Schiffman
-
29. Opposition to vaccination: a transatlantic discussion
- Prof. Jonathan Temte
-
30. Elective caesarean sections from an evolutionary perspective
- Prof. Wenda Trevathan
-
31. Antiphospholipid syndrome and Lupus
- Prof. Graham Hughes
-
32. Prescribing medications to children - a GP’s view
- Dr. Amanda Simmons
Topics Covered
- Amyloid build-up and the importance of early diagnosis
- The potential of inhibiting vs. clearing amyloid aggregation
- Different potential therapeutic approaches designed for different stages of Alzheimer’s
- The future of therapies targeting amyloid deposition
Biography
John Hardy is a geneticist and molecular biologist whose research interests focus on neurological disease. Dr. Hardy received his B.Sc. (Hons) degree from the University of Leeds, UK (1976) and his Ph.D. from Imperial College, London, UK where he studied dopamine and amino acid neuropharmacology. Dr. Hardy received his postdoctoral training at the MRC Neuropathogenesis Unit in Newcastle upon Tyne, UK and then further postdoctoral work at the Swedish Brain Bank in Umeå, Sweden where he started to work on Alzheimer’s disease. He became Assistant Professor of Biochemistry at St. Mary’s Hospital, Imperial College, London in 1985 and initiated genetic studies of Alzheimer’s disease whilst there. He was appointed Associate Professor in 1989 and then took the Pfeiffer Endowed Chair of Alzheimer’s Research at the University of South Florida, in Tampa in 1992. In 1996 he moved to the Mayo Clinic in Jacksonville, Florida, as Consultant and Professor of Neuroscience. He became Chair of Neuroscience in 2000 and moved to NIA as Chief of the Laboratory of Neurogenetics in 2001. He won the MetLife, the Allied Signal and the Potamkin Prize for his work in describing the first genetic mutations, in the amyloid gene in Alzheimer’s disease, in 1991. He was Head of the Neurogenetics Section, National Institute of Ageing, Bethesda, USA and in 2007 took up the Chair of Molecular Biology of Neurological Disease at the UCL Institute of Neurology. With over 23,000 citations, Prof Hardy is the most cited Alzheimer's disease researcher in the UK (5th internationally). In recognition of his exceptional contributions to science, he was elected a Fellow of the Royal Society in 2009. In 2016 Prof Hardy received the Breakthrough Prize in Life Sciences for his research on the cause of early-onset Alzheimer’s disease.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Hardy, J. (2018, April 1). Current directions in the prevention and treatment of Alzheimer’s disease [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 30, 2024, from https://doi.org/10.69645/VBTY5256.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. John Hardy, Consultant: Eisai Speaker's Bureau: Eli Lily Grant/Research Support (Principal Investiqator): MRC/Wellcome Trust